NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
school
University Rankings
subject
University Subject Rankings
place
Country Rankings
insights
i10 Productivity Rankings
insights
Subject Rankings
format_list_numbered
Top 100 Scientists
format_list_numbered
Citation Rankings
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Vinay Prasad
AD Scientific Index 2024
Others
University of California San Francisco - San Francisco / United States
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Vinay Prasad's MOST POPULAR ARTICLES
1-)
Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugsA Haslam, V PrasadJAMA network open 2 (5), e192535-e192535, 20196342019
2-)
Research and development spending to bring a single cancer drug to market and revenues after approvalV Prasad, S MailankodyJAMA internal medicine 177 (11), 1569-1575, 20174252017
3-)
A Decade of Reversal: An Analysis of 146 Contradicted Medical PracticesV Prasad, A Vandross, C Toomey, M Cheung, J Rho, S Quinn, SJ Chacko, ...Mayo Clinic Proceedings, 20134242013
4-)
Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvalsC Kim, V PrasadJAMA internal medicine 175 (12), 1992-1994, 20154092015
5-)
The high price of anticancer drugs: origins, implications, barriers, solutionsV Prasad, K De Jesús, S MailankodyNature reviews Clinical oncology 14 (6), 381-390, 20173982017
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept